What factors account for keytruda's higher price?

Keytruda (pembrolizumab) is priced high for several overlapping reasons—some are about drug economics (what it costs to make and develop) and some are about market dynamics and how payers decide value.

1) Cost of innovation and clinical development

• Extensive R&D: Immune-oncology drugs typically require large investment and long development timelines with many failed candidates.
• High cost per successful product: Even if Keytruda is successful, development costs across the whole program are substantial.

2) Manufacturing complexity (biologic drug)

• Keytruda is a monoclonal antibody (a biologic), not a small-molecule tablet.
• Biologics generally require specialized cell culture systems, purification steps, cold-chain logistics, and strict quality control, which increases cost.

3) Demand and broad clinical use

• Keytruda has multiple approvals across cancers and settings (e.g., adjuvant, metastatic, first-line in various tumor types).
• Wider indications generally increase overall demand, which can still keep prices high—especially if competitive alternatives are limited for certain patient groups.

4) Clinical impact and payer willingness to pay

• It can improve outcomes for many patients, sometimes producing durable responses (for a subset of patients).
• Pricing often reflects value-based considerations—how cost is weighed against survival/response benefit and the lack of equally effective alternatives.

5) Patent protection and exclusivity

• Keytruda has ongoing patent coverage (and regulatory exclusivity protections), which means no true generic or biosimilar can compete in most places/indications yet.
• Without biosimilar competition, manufacturers have more pricing power.

6) Health system negotiation and “list price” vs real price

• The “sticker price” you see publicly is often a list price.
• Actual prices can be affected by rebates, discounts, managed-entry agreements, patient assistance programs, and negotiated contracts with insurers and government systems.
• So the headline number may not reflect every payer’s net cost.

7) Worldwide market and risk management

• Manufacturers price globally while managing:
  • Regulatory and post-market obligations
  • Pharmacovigilance
  • Supply-chain and quality risks
  • Ongoing confirmatory trials in new indications

If you tell me your country (US, UK, Canada, EU, etc.) and whether you mean the list price per vial/infusion or what your insurer is paying, I can explain how pricing and discounts typically work there.